Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
Researchers noted that bridging while awaiting CAR-T manufacturing may not be appropriate for all patients, and in some cases, bridging was associated with worse PFS and OS.
Researchers found that CIRS scores are prognostic for overall and progression-free survival in patients with R/R DLBCL being evaluated for CAR-T therapy.
Despite improved survival in patients with B cell malignancies who are treated with PI3K inhibitors, researchers found incidences of pneumonitis, infections, and sepsis are higher in these patients.
AML survivors treated with blood or marrow transplantation have a greater risk of grade 3 or higher chronic health conditions, according to a survey that compared the long-term outcomes between survivors and their healthy siblings.
Data from the CIBMTR demonstrate a need to develop return-to-work interventions for patients who have undergone HCT as treatment of malignant, as well as nonmalignant, conditions.
Results of LAST, the largest study on TKI discontinuation, support using patient-reported outcomes when monitoring remission and symptoms in patients who discontinue TKI therapy.
Researchers explored the effect of using antibiotics commonly used to treat neutropenic fever on likelihood of aGVHD developing in younger patients who underwent HCT for acute leukemia.
Data from an ongoing trial of luspatercept, an erythroid maturation agent, in patients with myelofibrosis and anemia shows promise of clinically significant activity with low level of grade 3/4 adverse effects.
Using a computational approach, researchers detected the effect of dietary changes and antibacterial therapies on gut microbiota of patients who had undergone allo-HSCT, which may be associated with adverse events such as GVHD.
Researchers report on awareness and access to health information technology by minority patients and caregivers, as well as their interest in learning more about and using EMRs.